FI904827A0 - Kalciumkanalsammansaettningar och -foerfaranden. - Google Patents
Kalciumkanalsammansaettningar och -foerfaranden.Info
- Publication number
- FI904827A0 FI904827A0 FI904827A FI904827A FI904827A0 FI 904827 A0 FI904827 A0 FI 904827A0 FI 904827 A FI904827 A FI 904827A FI 904827 A FI904827 A FI 904827A FI 904827 A0 FI904827 A0 FI 904827A0
- Authority
- FI
- Finland
- Prior art keywords
- sub
- kalciumkanalsammansaettningar
- foerfaranden
- och
- subunits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17689988A | 1988-04-04 | 1988-04-04 | |
PCT/US1989/001408 WO1989009834A1 (en) | 1988-04-04 | 1989-04-04 | Calcium channel compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
FI904827A0 true FI904827A0 (fi) | 1990-10-01 |
Family
ID=22646350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI904827A FI904827A0 (fi) | 1988-04-04 | 1990-10-01 | Kalciumkanalsammansaettningar och -foerfaranden. |
Country Status (10)
Country | Link |
---|---|
US (3) | US5618720A (fi) |
EP (1) | EP0424397B1 (fi) |
JP (1) | JP3066398B2 (fi) |
AT (1) | ATE139542T1 (fi) |
AU (1) | AU3548089A (fi) |
CA (1) | CA1341170C (fi) |
DE (1) | DE68926713T2 (fi) |
DK (1) | DK173404B1 (fi) |
FI (1) | FI904827A0 (fi) |
WO (1) | WO1989009834A1 (fi) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846757A (en) * | 1988-04-04 | 1998-12-08 | Sibia Neurosciences, Inc. | Human calcium channel α1, α2, and β subunits and assays using them |
US5429921A (en) * | 1988-04-04 | 1995-07-04 | The Salk Institute Biotechnology/Industrial Assoc. Inc. | Assays for agonists and antagonists of recombinant human calcium channels |
US6096514A (en) * | 1988-04-04 | 2000-08-01 | Sibia Neurosciences, Inc. | Human calcium channel compositions and methods |
US6653097B1 (en) | 1991-08-15 | 2003-11-25 | Merck & Co., Inc. | Human calcium channel compositions and methods |
US5851824A (en) * | 1988-04-04 | 1998-12-22 | Sibia Neurosciences, Inc. | Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA |
US5386025A (en) * | 1990-02-20 | 1995-01-31 | The Salk Institute Biotechnology/Industrial Associates | Calcium channel compositions and methods |
US6387696B1 (en) | 1988-04-04 | 2002-05-14 | Merck & Co., Inc. | Human calcium channel compositions and methods |
US5876958A (en) * | 1988-04-04 | 1999-03-02 | Sibia Neurosciences, Inc. | Assays of cells expressing human calcium channels containing α1 β subunits |
JP3066398B2 (ja) * | 1988-04-04 | 2000-07-17 | メルク エンド カンパニー インコーポレーテッド | カルシウムチャンネル組成物および製造方法 |
US5874236A (en) * | 1988-04-04 | 1999-02-23 | Sibia Neurosciences. Inc. | DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits |
US20040018510A1 (en) | 1990-11-08 | 2004-01-29 | Merck & Co., Inc. | Human calcium channel compositions and methods |
US5369028A (en) * | 1990-04-03 | 1994-11-29 | The Salk Institute Biotechnology/Industrial Associates, Inc. | DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same |
US6440681B1 (en) | 1990-04-03 | 2002-08-27 | Merck & Co., Inc. | Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors |
US5401629A (en) * | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
ES2157197T3 (es) | 1990-09-13 | 2001-08-16 | Univ Duke | Expresion de receptores acoplados a una proteina g en levadura. |
DE4110785A1 (de) * | 1991-04-04 | 1992-10-08 | Bayer Ag | Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung |
US6229000B1 (en) | 1991-04-04 | 2001-05-08 | Bayer Aktiengesellschaft | Tissue-specific human neuronal calcium channel subtypes and their use |
CA2113203C (en) * | 1991-08-15 | 2001-01-02 | Michael Miller Harpold | Human calcium channel compositions and methods |
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
ATE312347T1 (de) * | 1991-08-23 | 2005-12-15 | Nps Pharma Inc | Screening-verfahren für kalzium-rezeptor aktive verbindungen |
US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
AU3582593A (en) * | 1992-01-10 | 1993-08-03 | Sloan-Kettering Institute For Cancer Research | Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
GB2286397B (en) * | 1993-03-08 | 1997-09-10 | Salk Inst Biotech Ind | Human neuronal nicotinic acetylcholine receptor compositions and methods of employing same |
US6255059B1 (en) | 1993-03-31 | 2001-07-03 | Cadus Pharmaceutical Corporation | Methods for identifying G protein coupled receptor effectors |
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
US7235648B1 (en) | 1993-03-31 | 2007-06-26 | Cadus Technologies, Inc. | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
US5912122A (en) | 1993-06-04 | 1999-06-15 | Sibia Neurosciences, Inc. | Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6 |
US6090623A (en) * | 1993-08-11 | 2000-07-18 | Merck & Co., Inc. | Recombinant human calcium channel β4 subunits |
AU1091595A (en) * | 1993-11-08 | 1995-05-29 | Salk Institute Biotechnology/Industrial Associates, Inc., The | Human neuronal nicotinic acetylcholine receptor compositions and methods employing same |
US6800452B1 (en) * | 1994-08-08 | 2004-10-05 | Science Applications International Corporation | Automated methods for simultaneously performing a plurality of signal-based assays |
DE122005000033I2 (de) | 1994-10-21 | 2006-11-23 | Nps Pharma Inc | Kalzium-Receptor aktive Verbindungen |
US5623051A (en) * | 1994-11-10 | 1997-04-22 | University Of Washington | Methods and compositions for screening for presynaptic calcium channel blockers |
US6485967B1 (en) | 1995-06-07 | 2002-11-26 | Merck & Co., Inc. | Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid |
PT907631E (pt) | 1996-05-01 | 2003-10-31 | Nps Pharma Inc | Compostos inorganicos activos como receptores de ioes |
US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
US6528630B1 (en) * | 1997-12-03 | 2003-03-04 | Merck & Co., Inc. | Calcium channel compositions and methods |
CA2299611A1 (en) | 1998-06-02 | 1999-12-09 | Torben Bech-Hansen | Retinal calcium channel (alpha)1f-subunit gene |
US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
US7524643B2 (en) | 2001-04-11 | 2009-04-28 | Ortho-Mcneil Pharmaceutical, Inc. | CDNA encoding the human alpha2 delta4 calcium channel subunit |
US7049084B2 (en) | 2001-05-30 | 2006-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroblastoma cell lines expressing the α2δ subunit of calcium channels and methods therefore |
CN100560131C (zh) | 2001-10-22 | 2009-11-18 | 斯克里普斯研究学院 | 抗体靶向化合物 |
US20040009537A1 (en) * | 2002-01-11 | 2004-01-15 | Jack Roos | Methods of modulating and of identifying agents that modulate intracellular calcium |
CA2667972A1 (en) | 2006-10-30 | 2008-05-08 | Michael Tovey | Gene reporter assay, kit and cells with improved sensitivity and/or specificity for determining the level of an extracellular signal |
WO2008133867A1 (en) * | 2007-04-26 | 2008-11-06 | Merck & Co., Inc. | 2-substituted indole derivatives as calcium channel blockers |
CA2701203A1 (en) * | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
US8304434B2 (en) * | 2007-10-04 | 2012-11-06 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
EP2205079A4 (en) * | 2007-10-04 | 2010-10-27 | Merck Sharp & Dohme | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS |
EP2252608A4 (en) | 2008-02-29 | 2012-10-03 | Vm Discovery Inc | METHOD FOR TREATING PAIN SYNDROME AND OTHER SUFFERING |
CA2749142A1 (en) | 2008-03-04 | 2009-09-11 | Biomonitor Limited | Cell, method and kit for conducting an assay for neutralizing antibodies |
US20090270413A1 (en) * | 2008-04-28 | 2009-10-29 | Galemmo Jr Robert | Di-t-butylphenyl piperazines as calcium channel blockers |
WO2009132452A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Diaryl-cyclylalkyl derivatives as calcium channel blockers |
US20090270394A1 (en) * | 2008-04-28 | 2009-10-29 | Galemmo Jr Robert | Cyclylamine derivatives as calcium channel blockers |
CA2738395A1 (en) * | 2008-09-29 | 2010-04-01 | Prasun K. Chakravarty | Substituted aryl sulfone derivatives as calcium channel blockers |
WO2011053542A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
EP2831071B1 (en) | 2012-03-29 | 2018-11-14 | Merck Sharp & Dohme Corp. | Imidazolyl methyl piperidine t-type calcium channel antagonists |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0046790A4 (en) * | 1980-02-25 | 1983-01-31 | Richard Axel | USE OF EUKARYOTIC PROMOTOR SEQUENCES IN THE PRODUCTION OF PROTEIN MATERIAL. |
US4788135A (en) * | 1983-03-07 | 1988-11-29 | The Board Of Trustees Of The Leland Stanford, Jr. University | System for efficient isolation of genes using probes |
US4912202A (en) * | 1987-01-08 | 1990-03-27 | Miles Inc. | Dihydropyridine receptor and antibodies thereto |
US4906564A (en) * | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
US5024939A (en) | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US4954436A (en) * | 1987-08-06 | 1990-09-04 | Trustees Of Dartmouth College | Dihydropyridine-sensitive calcium channel as a tumor associated marker |
US4950739A (en) | 1988-02-10 | 1990-08-21 | New York University | Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels |
US5429921A (en) * | 1988-04-04 | 1995-07-04 | The Salk Institute Biotechnology/Industrial Assoc. Inc. | Assays for agonists and antagonists of recombinant human calcium channels |
JP3066398B2 (ja) * | 1988-04-04 | 2000-07-17 | メルク エンド カンパニー インコーポレーテッド | カルシウムチャンネル組成物および製造方法 |
US5846757A (en) * | 1988-04-04 | 1998-12-08 | Sibia Neurosciences, Inc. | Human calcium channel α1, α2, and β subunits and assays using them |
US5876958A (en) * | 1988-04-04 | 1999-03-02 | Sibia Neurosciences, Inc. | Assays of cells expressing human calcium channels containing α1 β subunits |
US5407820A (en) * | 1988-04-04 | 1995-04-18 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Calcium channel α-2 subunit DNAs and cells expressing them |
US5386025A (en) * | 1990-02-20 | 1995-01-31 | The Salk Institute Biotechnology/Industrial Associates | Calcium channel compositions and methods |
US5851824A (en) * | 1988-04-04 | 1998-12-22 | Sibia Neurosciences, Inc. | Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA |
US5874236A (en) * | 1988-04-04 | 1999-02-23 | Sibia Neurosciences. Inc. | DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits |
US5189020A (en) * | 1989-11-22 | 1993-02-23 | Neurex Corporation | Method of reducing neuronal damage using omega conotoxin peptides |
US5051403A (en) * | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
US5264371A (en) * | 1989-11-22 | 1993-11-23 | Neurex Corporation | Screening method for neuroprotective compounds |
US5401629A (en) * | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
AU1258292A (en) * | 1991-01-18 | 1992-08-27 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of hematopoietic growth factor genes |
DE4110785A1 (de) * | 1991-04-04 | 1992-10-08 | Bayer Ag | Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung |
WO1993008469A1 (en) * | 1991-10-23 | 1993-04-29 | Trustees Of Dartmouth College | Recombinant calcium channel polypeptides |
AU3582593A (en) * | 1992-01-10 | 1993-08-03 | Sloan-Kettering Institute For Cancer Research | Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof |
DE4222126A1 (de) * | 1992-02-17 | 1993-08-19 | Bayer Ag | Humane neuronale beta-untereinheiten spannungsabhaengiger calciumkanaele und deren verwendung |
WO1994002511A1 (en) * | 1992-07-27 | 1994-02-03 | Pfizer Inc. | Calcium channel blocking polypeptide from agelenopsis aperta |
DE69426033T2 (de) | 1993-07-30 | 2001-05-17 | Elan Pharm Inc | Für die alpha-1e untereinheit des menschlichen kalziumkanals kodierende dna |
US5712158A (en) * | 1995-06-06 | 1998-01-27 | Warner-Lambert Company | Cell line for the rapid expression of functional calcium channels |
-
1989
- 1989-04-04 JP JP1505007A patent/JP3066398B2/ja not_active Expired - Lifetime
- 1989-04-04 EP EP89905292A patent/EP0424397B1/en not_active Expired - Lifetime
- 1989-04-04 CA CA000595588A patent/CA1341170C/en not_active Expired - Fee Related
- 1989-04-04 WO PCT/US1989/001408 patent/WO1989009834A1/en active IP Right Grant
- 1989-04-04 DE DE68926713T patent/DE68926713T2/de not_active Expired - Lifetime
- 1989-04-04 AT AT89905292T patent/ATE139542T1/de not_active IP Right Cessation
- 1989-04-04 AU AU35480/89A patent/AU3548089A/en not_active Abandoned
-
1990
- 1990-10-01 FI FI904827A patent/FI904827A0/fi not_active IP Right Cessation
- 1990-10-04 DK DK199002400A patent/DK173404B1/da not_active IP Right Cessation
-
1995
- 1995-02-15 US US08/404,354 patent/US5618720A/en not_active Expired - Fee Related
- 1995-03-13 US US08/404,950 patent/US7063950B1/en not_active Expired - Fee Related
-
1997
- 1997-06-27 US US08/884,599 patent/US6013474A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE68926713T2 (de) | 1996-11-14 |
AU3548089A (en) | 1989-11-03 |
WO1989009834A1 (en) | 1989-10-19 |
DK240090D0 (da) | 1990-10-04 |
US6013474A (en) | 2000-01-11 |
EP0424397A4 (en) | 1992-08-12 |
EP0424397A1 (en) | 1991-05-02 |
DE68926713D1 (de) | 1996-07-25 |
EP0424397B1 (en) | 1996-06-19 |
JP3066398B2 (ja) | 2000-07-17 |
DK240090A (da) | 1990-10-04 |
ATE139542T1 (de) | 1996-07-15 |
CA1341170C (en) | 2001-01-16 |
US5618720A (en) | 1997-04-08 |
US7063950B1 (en) | 2006-06-20 |
DK173404B1 (da) | 2000-09-25 |
JPH04503152A (ja) | 1992-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI904827A0 (fi) | Kalciumkanalsammansaettningar och -foerfaranden. | |
ATE242324T1 (de) | Menschliche kalziumkanale und verwendungen davon | |
ES2147184T3 (es) | Composiciones de canales calcicos humanos y procedimientos. | |
DE69836229D1 (de) | Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren | |
ES552627A0 (es) | Procedimiento para la preparacion de carbamatos de fenilo | |
ES8900017A1 (es) | Procedimiento para la preparacion de dipeptidos de n,n-dialquil-guanidino. | |
ATE250571T1 (de) | Kaliumkanal-blocker | |
TR199901386T2 (en) | �midazopiridazinler. | |
ES553033A0 (es) | Procedimiento para la obtencion de compuestos de b-lactama | |
ES2165358T3 (es) | Utilizaciones de la proteinquinasa de neurofilamento/tau pk40. | |
AU7999687A (en) | Active compounds for preventing tumor metastases | |
IE55801B1 (en) | Novel vitamin d analogs | |
MY102026A (en) | Antiasthmatic. | |
DE69428909D1 (de) | Für die immun- und cns-therapie nutzbare, neuartige tripeptide | |
SE8501412D0 (sv) | Teltenhet | |
SE8402656L (sv) | Tillsatsanordning for netdorrar | |
ES2038638T3 (es) | Sustancias moduladoras del canal del calcio. | |
SE8605341L (sv) | Blaffmetoden | |
SE8405321D0 (sv) | Anordning vid rullstol | |
SE8604921L (sv) | Rengoringsprodukt | |
MX9709982A (es) | Retinoides de chalcona y uso de los mismos. | |
SU1746666A1 (ru) | Замещенные 3-аминометиленпирролидин-2,4-дионы, обладающие противосудорожной активностью |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed |
Owner name: THE SALK INSTITUTE BIOTECHNOLOGY/ |